Drug Trial Radar · NCT05865535
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jun 13, 2023
Primary completion
Aug 11, 2026
Study completion Sep 25, 2026
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Conditions
- Cachexia
Interventions
AV-380Biological
AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of adverse events (AEs)Time frame: From enrollment to the last follow-up visit approximately 60-days post dose
- ToxicityTime frame: While receiving study drug (up to 4 months)
- Laboratory AbnormalitiesTime frame: From enrollment to the last follow-up visit approximately 60-days post dose.
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Beverly Hills Cancer Center
Beverly Hills, California
Cancer and Blood Specialty Clinic
Lakewood, California
Hoag Memorial Hospital
Newport Beach, California
Hartford Hospital
Hartford, Connecticut
Advent Health Orlando Hospital
Orlando, Florida
Nebraska Cancer Specialists
Omaha, Nebraska
Astera Cancer Care
East Brunswick, New Jersey
New York Cancer And Blood Specialists
Shirley, New York
Oregon Health and Science University
Portland, Oregon
MUSC Hollings Cancer Center
Charleston, South Carolina
Vanderbilt University Henry-Joyce Cancer Clinic
Nashville, Tennessee
Community Clinical Trials
Kingwood, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.